Intellectus Partners’s AstraZeneca AZN Stock Holding History

Intellectus Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,408	Closed	-$319K	–	255
2022 Q1	$319K	Sell	2,408 -173	-7%	-$20.7K	0.1%	194
2021 Q4	$301K	Buy	2,581 +524	+25%	+$61.7K	0.08%	215
2021 Q3	$247K	Buy	+2,057	New	+$239K	0.06%	241
2019 Q2	–	Sell	-100	Closed	-$8K	–	205
2019 Q1	$8K	Hold	100	–	–	﹤0.01%	358
2018 Q4	$8K	Hold	100	–	–	0.01%	206
2018 Q3	$8K	Hold	100	–	–	﹤0.01%	489
2018 Q2	$7K	Hold	100	–	–	﹤0.01%	504
2018 Q1	$7K	Hold	100	–	–	﹤0.01%	501
2017 Q4	$7K	Hold	100	–	–	﹤0.01%	512
2017 Q3	$7K	Hold	100	–	–	﹤0.01%	648
2017 Q2	$7K	Hold	100	–	–	﹤0.01%	629
2017 Q1	$6K	Hold	100	–	–	﹤0.01%	570
2016 Q4	$5K	Buy	+100	New	+$5.68K	﹤0.01%	584

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Intellectus Partners's AZN Position: Q2 2022 in Review

Intellectus Partners sold out of AstraZeneca (AZN) in Q2 2022, closing a stake of 2,408 shares — an estimated $319K sold.

Intellectus Partners first reported a position in AZN in Q4 2016 and held it in 13 quarters. The position peaked at $319K in Q1 2022. 1,015 funds tracked by Wall St. Rank hold AZN as of Q2 2022.

Intellectus Partners reported no remaining AstraZeneca position as of Q2 2022 after selling out during the quarter.
Intellectus Partners sold 2,408 AstraZeneca shares in Q2 2022, an estimated $319K.
Intellectus Partners first reported a position in AstraZeneca in Q4 2016 and held it in 13 quarters.
Intellectus Partners's AstraZeneca position peaked at $319K in Q1 2022.
1,015 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2022.

Based on Intellectus Partners's 13F filing for Q2 2022, filed 12 Aug 2022.